BSTG Stock Price, News & Analysis

Biostage, Inc. (OTCQB: BSTG) has officially activated Mayo Clinic as the first site for its clinical trial in severe esophageal disease. This marks Biostage's first clinical trial in the United States for its esophageal implant technology, which aims to regenerate organs inside the body. The Phase 1, first-in-human study approved by the FDA will evaluate both safety and efficacy in up to ten patients requiring the removal of up to 6 cm of their esophagus due to cancer, trauma, or birth defects.

The study will be conducted at up to five hospitals in the U.S., with the primary endpoint being the development of a continuous biological neo-conduit at three months following implantation. This milestone represents a significant step forward for Biostage in its mission to advance organ regeneration and regenerative medicine.

Biostage, Inc. (OTCQB: BSTG) has appointed Ron Packard as an independent director to its Board of Directors, enhancing its strategy and innovation capabilities. Packard brings extensive experience in business and finance, previously leading K12 Inc. to nearly $1 billion in revenue and guiding its IPO. His leadership will be crucial as Biostage focuses on its cell-therapy advancements, particularly the Biostage Esophageal Implant, for treating esophageal cancer. Biostage's technology has already shown promise, achieving successful regeneration of the esophagus in clinical cases. The company holds 12 U.S. patents and two orphan-drug designations from the FDA, indicating potential market exclusivity. Packard expressed enthusiasm about supporting Biostage's mission to address unmet patient needs through its innovative therapies.

Biostage, Inc. (OTCQB: BSTG) announced a private placement raising approximately $6 million to accelerate the clinical development of the Biostage Esophageal Implant (BEI). The FDA has approved a phase one and two clinical trial for adults to repair esophageal damage caused by cancer or injury, with potential future expansion for pediatric use. The company is also exploring applications of its technology for lung cancer treatment with the Biostage Bronchial Implant. The private placement involved the sale of 1,000,967 shares at a price of $6.00 per share, with $3.6 million received so far. The announcement highlighted the company's commitment to advancing regenerative medicine technologies, specifically targeting gastrointestinal and airway disorders.

Biostage, Inc. announced a leadership transition effective March 1, 2023. Existing board member Jerry He replaces David Green as Chairman and CEO, while Green continues on the Board to assist in the transition. Jerry He previously served as Executive Vice Chairman of Bright Scholar Education Holdings Limited and has a strong background in biotechnology and finance. Biostage develops regenerative medicine solutions for gastrointestinal and airway disorders. The company is preparing for FDA-approved clinical trials aimed at treating esophageal cancer, a condition impacting many patients with a low survival rate.

Biostage, Inc. (OTCQB: BSTG) announces a leadership transition, appointing Jerry He as the new Chairman and Chief Executive Officer effective March 1, 2023. He replaces David Green, who will remain on the Board to support the transition. Mr. He has significant experience in the biotechnology and education sectors, previously serving as CEO of Bright Scholar Education Holdings. The company is advancing towards FDA-approved clinical trials for regenerative treatments targeting esophageal cancer. This clinical approach could significantly impact the treatment landscape, as esophageal cancer has a high mortality rate.

On January 11, 2023, Biostage, Inc. (OTCQB: BSTG) officially appointed David Green as Chief Executive Officer by removing his Interim title. The updated employment agreement will include amendments to his existing terms. Green, a founder of the company, expressed his commitment to advancing Biostage's FDA-approved clinical trials and expanding its treatment pipeline for gastro-intestinal and airway disorders. Biostage has achieved significant milestones, including the world's first successful esophagus regeneration in 2017 and holds 12 U.S. patents along with two orphan-drug designations.

Biostage, a biotechnology company, announced plans to initiate patient recruitment for its first clinical trial in early 2023. The company published a study in the Journal of Immunology and Regenerative Medicine, demonstrating the effectiveness of its Biostage Esophageal Implant (BEI) in stimulating tissue regeneration in nine pigs. The BEI facilitated new blood vessel growth and allowed for the regeneration of a continuous biological conduit by 28 days. This aligns with Biostage's FDA-approved clinical trial objective of achieving similar results within 90 days.